Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.

Item
http://www.wikidata.org/entity/Q34316070
The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic AnalysisEfficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic ReviewAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerLocalization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesEvaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].Clinical meta-analyses of targeted therapies in adenocarcinoma.Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.
P2860

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.

Item
http://www.wikidata.org/entity/Q34316070
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Chemotherapy plus multitargete ...... randomized controlled trials.
@ast
Chemotherapy plus multitargete ...... randomized controlled trials.
@en
Chemotherapy plus multitargete ...... randomized controlled trials.
@nl
type
label
Chemotherapy plus multitargete ...... randomized controlled trials.
@ast
Chemotherapy plus multitargete ...... randomized controlled trials.
@en
Chemotherapy plus multitargete ...... randomized controlled trials.
@nl
prefLabel
Chemotherapy plus multitargete ...... randomized controlled trials.
@ast
Chemotherapy plus multitargete ...... randomized controlled trials.
@en
Chemotherapy plus multitargete ...... randomized controlled trials.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Chemotherapy plus multitargete ...... randomized controlled trials.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921